Larimar Therapeutics, Inc. (LRMR) analyst actions
Rating and price-target actions on LRMR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the LRMR overview →
2 measured LRMR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 | Press release | +8.99% | +3.36% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Larimar Therapeutics, Inc. (LRMR) And Encourages Shareholders to Reach Out | Press release | +0.09% | -5.61% |
Keep exploring
More LRMR: earnings → · SEC filings → · LRMR overview →